COMBINED EFFECT OF HPMC K100M AND EUDRAGIT L/100-55 ON RELEASE RATE OF ANTICONVULSANT DRUG

The present study aims to check the influence of HPMC K100M and Eudragit L/100-55 on the Divalproex sodium release from modified release tablet dosage form. Divalproex sodium, an anticonvulsant/epileptic agent, is used in the effective management of bipolar disorders, mania, seizures, convulsions and tremors/epilepsy. The current research objective was to achieve 90% of drug release at 8-12 hrs. Extended-release tablets of Divalproex sodium were prepared using various proportions of Eudragit L/100-55, HPMC K100M by direct compression technique. Nine formulations were developed and characterized for pharmacopoeial limits. Results for all evaluation tests were found satisfactory. Drug release profiles were subjected to kinetic modeling to determine the kinetic parameters. Formulation (DEH5) containing equal quantities i.e. 31.25 mg of Eudragit L/100-55 and HPMC K100M, was found to be the best formulation showing similarity factor f2=85.75 and difference factor f1=2.29 with the reference marketed product (DIVALEX). Formulation DEH5 followed zero order, whereas release mechanism was non-Fickian type transport. {Article No. 181} doi:10.21276/bpr.2024.14.1.1